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We evaluated whether BNP has additive value to SPECT in patients with normal left ventricular (LV) systolic function. Data from
224 consecutive patients who underwent rest 201Tl-dipyridamole stress 99mTc-sestamibi gated SPECT and coronary angiography
due to chest pain were analyzed. Patients with true positive SPECT showed signiﬁcant higher BNP level than those with false
positive defect (38.5 (19.0–79.8) versus 19.0 (9.3–35.8), P = .01). Patients with true negative SPECT also showed signiﬁcantly
lowerBNPlevelthanthosewithfalsenegativeSPECT(39.0(23.0–77.0)versus22.0(15.0–43.0),P = .002).Inmultivariateanalyses,
elevated BNP level (using a cut-oﬀ value of 23.0pg/mL) was the strongest and independent predictor of CAD in overall patients
(OR 2.75, 95% CI: 1.50–5.023, P = .001) and patients with positive SPECT (OR 3.34, 95% CI: 1.51–7.37, P = .003). The area
under the receiver-operating characteristic curve for CAD in overall patients and patients with positive SPECT was 0.673 (95% CI:
0.603–0.743, P<. 001) and 0.694 (95% CI: 0.602–0.786, P<. 001), respectively. This study suggests that BNP level has additive
diagnostic value to SPECT ﬁndings in predicting CAD in patients with normal LV systolic function.
1.Introduction
Previous studies have reported that B-type natriuretic
peptide (BNP), synthesized as pre-proBNP mainly in the
ventricular myocardium and secreted in response to ventric-
ular volume and pressure overload, has close relation with
angiographic severity and could be a potential biomarker for
myocardial ischemia even in patients with preserved LV sys-
tolic function [1–4]. In patients with coronary artery disease,
myocardialischemiamaycausetransientleftventricular(LV)
systolic and diastolic dysfunction and consequently increase
LV wall stress, leading to elevated plasma natriuretic peptide
level or directly promotes the release of natriuretic peptide
independent from left ventricular wall stress [5, 6]. Recently,
it was discovered that natriuretic peptides are associated
with exercise-induced myocardial ischemia in patients with
coronaryarterydiseaseandBNPlevelatrestcansigniﬁcantly
improve diagnostic power of treadmill test in patients with
suspectedcoronaryarterydiseaseandnormalleftventricular
ejection fraction [7–11].
Stress myocardial perfusion imaging is also widely used
noninvasive modality for the diagnosis and risk stratiﬁcation
of patients with suspected myocardial ischemia [12, 13]. The
incidence of myocardial perfusion abnormalities at rest or
during stress is a hallmark of coronary artery disease [14].
The sensitivity of stress technetium-99m sestamibi single2 Cardiology Research and Practice
photonemissioncomputedtomography(SPECT)fordetect-
ing coronary artery disease has been reported to exceed 90%,
the speciﬁcity ranges between 53% and 100%. However, the
diagnostic accuracy of SPECT is profoundly inﬂuenced by
the presence of tissue attenuation such as diaphragm or
breast [15]. Also, in patients with multivessel coronary artery
disease, the perfusion abnormalities may be unremarkable
or even missed due to relatively balanced hypoperfusion
between the stenosed vessels [16]. Therefore, combining
natriuretic peptides as markers for inducible myocardial
ischemia may be useful for boosting diagnostic accuracy
of SPECT. In this study, we investigated the relationship
of BNP level with inducible myocardial ischemia on stress
technetium-99m sestamibi myocardial SPECT and evaluated
whether combining BNP measurement with SPECT could
improve diagnostic accuracy to predict signiﬁcant coronary
artery disease in patients with normal LV systolic function.
2.MaterialandMethods
2.1. Patients. This study analyzed patients who underwent
rest 201Tl/stress
99mTc sestamibi dual-isotope myocardial
perfusion SPECT with dipyridamole stress and coronary
angiography for evaluation of chest pain at Seoul National
University Hospital between December 2005 and February
2007. Patients with atrial ﬁbrillation, signiﬁcant valvular
heart disease, or renal insuﬃciency (creatinine clearance
by Cockcroft and Gault equation ≤25mL/min or serum
creatinine ≥2.3mg/dL) were excluded to avoid confounding
increase in BNP level due to causes other than myocardial
ischemia per se. We also excluded patients with evidence
of myocardial infarction (pathologic Q waves in the resting
electrocardiogram) and ﬁxed perfusion defect on the SPECT
to diﬀerentiate the patients with “inducible myocardial
ischemia” from those with irreversible myocardial injury
(scar).
2.2.SPECTImage AcquisitionandReconstruction. Rest 201Tl-
dipyridamole stress
99mTc-sestamibi gated SPECT was per-
formed prior to coronary angiography. First, 111MBq 201Tl
was injected and rest SPECT was performed using a dual-
head camera (Vertex EPIC; ADAC Laboratories) equipped
with a low-energy high-resolution collimator. Dipyridamole
(0.56mg/kg) was then injected over 4 minutes and 925MBq
99mTc-sestamibi was injected 3 minutes after stress. Gated
99mTc-sestamibi SPECT was performed 90 minutes after
stress using the same camera. Thirty-two step-and-shoot
images were acquired at intervals of 3◦ over 25s per step. For
gating,16framespercardiaccyclewithapreﬁxedRRinterval
and40%windowswereused. 201TlSPECTwasreconstructed
using a Butterworth ﬁlter with a cut-oﬀ frequency of 0.35
c y c l e sp e rp i x e la n da no r d e ro f1 0a n d
99mTc-sestamibi
SPECT was reconstructed using a Butterworth ﬁlter with a
cut-oﬀ frequency of 0.45 cycles per pixel and an order of 10.
2.3. Interpretation for Perfusion Abnormalities. For regional
analysis, the myocardium was divided into 20 segments,
and segmental perfusion and thickening were quantiﬁed
using automatic quantifying software (AutoQUANT; ADAC
Laboratories), which awarded a quantitative value and
scored the segment according to 4-point scoring system,
0 for normal uptake, 1 for mildly decreased uptake, 2 for
moderately decreased uptake and 3 for perfusion defect. The
perfusion abnormality at each segment was attributed to
each artery territory (left anterior descending, circumﬂex
and right coronary artery). For determining the perfu-
sion abnormalities, we took into consideration not only
computer-based interpretation but also physician analysis
to avoid the false positive perfusion abnormalities due to
attenuation defect especially in women. We used three
nuclear variables, summed stress score (SSS), summed rest
score (SRS), and summed diﬀerence score (SDS). SSS was
obtained by calculating the sum of scores of 20 segments
of stress
99mTc-sestamibi images. SRS was calculated on a
similar basis. Summed diﬀerence (reversibility) score (SDS)
was determined by the sum of diﬀerences between the SSS
and SRS in each segment. According to SSS, we considered
myocardial ischemia as mild (between 4 and 8), moderate,
(9–13) and severe (>13) [17].
2.4. Calculation of Ventricular Volumes and Ejection Fraction
in SPECT. Short-axis tomographic images were further
processed using Cedars quantitative gated SPECT (QGS)
software. The LV ejection fraction (LVEF), end-systolic vol-
ume (ESV) and end-diastolic volume (EDV) were calculated
automatically by Cedars QGS software after making three-
dimensionalsurfaceimagesofendocardiumandepicardium.
2.5. Coronary Angiography. In our study, coronary angiog-
raphy was considered as the gold standard method of
imaging coronary stenoses. All patients underwent coronary
angiography by the standard techniques. Intracoronary
nitroglycerin (0.1–0.2mg) was administered into aﬀected
coronary artery, just before the acquisition of the coronary
angiogram. The degree of stenosis was expressed as percent-
age of reduction in the internal luminal diameter in relation
to normal reference. Patients with >70% diameter stenosis
in any of the three major coronary arteries (left anterior
descending, circumﬂex and right coronary artery) or any
major large branch with more than 2mm in diameter were
considered to have signiﬁcant CAD (for left main, ≥50%
diameter stenosis).
2.6. Echocardiography. An M-mode and 2D transthoracic
echocardiography (TTE) was performed in all patients prior
to coronary angiography. All patients showed normal LV
systolic function (LVEF ≥ 50%) and no regional wall
motion abnormalities. Peak early (E) and late (A) diastolic
transmitral Doppler ﬂow velocities were obtained from
apical four-chamber view using pulsed wave Doppler, with
sample volume positioned at the mitral valve tip.
2.7. BNP Assay. All the venous blood samples were collected
in EDTA tubes for measurement of BNP levels. Assays
for BNP were performed with a Triage B-type Natriuretic
Peptide test (Biosite Diagnostics, Inc., San Diego, California)Cardiology Research and Practice 3
which is ﬂuorescence immunoassay for the quantitative
determinationofBNPinwholebloodandplasmaspecimens,
with a turnaround time of 15 minutes and measurement
range of 5–5000pg/mL [18, 19]. This method correlates
the ﬂuorescence measurement to BNP concentration by
using an internal calibration curve. In a previous study by
Wieczorek et al., the coeﬃcient of variation (CV) for intra-
assay precision was 9.5% at 28.8pg/mL, 12.0% at 584pg/mL,
and 13.9% at 1180pg/mL. The CV for intrassay precision
was 10% at 28.8pg/mL, 12.8% at 584pg/mL, and 14.8%
at 1180pg/mL. The CV for interassay variation was 10% at
28.8pg/mL, 12.4% at 584pg/mL, and 14.8% at 1180pg/mL
[20].
2.8.StatisticalAnalysis. Continuousvariableswerepresented
as mean values ± standard deviations (SD) except BNP data
(median with interquartile). BNP was log-transformed for
analyses because of its skewed distribution. Within-group
comparisonswereperformedwiththeMann-WhitneyU test
or Kruskal-Wallis test. A measure of the linear association
between two variables was evaluated using Spearman’s rank
statistics and all statistical tests were two-tailed. A multi-
variate regression analysis was performed on variables found
to be signiﬁcant predictors of CAD in univariate analysis.
Cut-oﬀ values for BNP were determined by performing
receiver-operating characteristic (ROC) curve analysis. To
evaluate the diagnostic performance of BNP and SPECT,
sensitivity, speciﬁcity, positive and negative predictive values
were calculated. A P value of <.05 was considered as
signiﬁcant. The statistical package used was SPSS 13.0 (SPSS
Inc. Chicago, Illinois, USA).
3. Results
3.1. Baseline Characteristics. The baseline characteristics are
presented in Table 1. Patients were categorized according to
the SPECT results. The patients (n = 224) were 62.6 years
old, and 60.7% of them were men. Patients with signiﬁcant
coronary artery disease were 121 (54.0%) patients. SPECT
was true positive in 94/142 (61.8%) and true negative in
55/82 (67.1%). Patients with true positive SPECT (n =
94) were older (P = .007) and had a signiﬁcantly higher
prevalence of hypertension (P = .03) than those with
false positive SPECT (n = 48). Patients with true positive
SPECT had signiﬁcantly higher summed stress score and
summed diﬀerence score than those with false positive
SPECT (P<. 001 for all). In patients with negative SPECT
(n = 82), patients with false negative SPECT (n = 27)
had a signiﬁcantly lower HDL-C level (P<. 01) and
creatinine clearance (P = .01) and showed a signiﬁcantly
higher prevalence of diabetes (P = .02) and hypertension
(P = .03) than those with true negative SPECT. Patients
with true positive SPECT showed signiﬁcant higher BNP
than those with false positive defect (38.5 (19.0–79.8) versus
19.0 (9.3–35.8), P = .01). Patients with true negative
SPECT also showed signiﬁcantly lower BNP than those with
false negative SPECT (39.0 (23.0–77.0) versus 22.0 (15.0–
43.0), P = .002). There was no signiﬁcant diﬀerence in
left ventricular ejection fraction, left ventricular/atrial size
(LVESV, LVEDV, LA), and several Doppler parameters in
echocardiography(E wave velocity, Awavevelocity,E/Aratio
and deceleration time) between each group.
3.2. Correlation between BNP and Clinical Variables, Echocar-
diographic and SPECT Parameters. The correlations of log-
arithmically transformed BNP with clinical variables and
parameters of echocardiography and SPECT are shown in
Table 2. Logarithmically transformed BNP showed a signif-
icant correlation with age (r = 0.367, P<. 001) and A wave
(r = 0.194, P<. 008) and a signiﬁcant inverse correlation
with creatinine clearance (r =− 0.226, P = .001) in overall
patients(Table 2).Therewasalsosimilarcorrelationbetween
logarithmically transformed BNP and these variables in
patients with true positive SPECT (Table 2).
Analyzed in terms of the severity or extent of myocardial
ischemia detected in SPECT, there was a signiﬁcant correla-
tion between logarithmically transformed BNP and summed
rest score (perfusion defect at rest) in patients (r = 0.249,
P<. 001) and those with positive SPECT (r = 0.309,
P = .001) (Table 2). Although summed diﬀerence score
(reversible ischemia) also showed a signiﬁcant correlation
with logarithmically transformed BNP in patients with
positive SPECT (r = 0.172, P = .043), the correlation was
muchweakerthansummedrestscore.Accordingtosummed
stress score, patients were divided as mild (between 4 and 8),
moderate (9–13), and severe (>13) ischemia. Patients with
severe myocardial ischemia (SSS > 13) showed signiﬁcantly
higher BNP level than those with mild or moderate ischemia
and there was no signiﬁcant diﬀerence in BNP level between
those with mild and moderate ischemia (Figure 1). Similarly,
there was also no signiﬁcant diﬀerence in BNP level between
those with single vessel disease and multivessel disease in
angiography(44.5(21.8–84.5)versus31.0(18.0–65.0)(13.0–
37.0), P>. 05) (Figure 1).
3.3. Multivariate Analysis for Predictors of Coronary Artery
Disease. In multivariate analyses, elevated BNP level (using
a cut-oﬀ value of 23.0pg/mL) was a signiﬁcant independent
predictor of coronary artery disease in overall patients (OR
2.75, 95% CI: 1.50–5.023, P = .001) and patients with
positive SPECT (OR 3.34, 95% CI: 1.51–7.37, P = .003)
(Table 3). In patients with negative SPECT, however, BNP
level was not an independent predictor for signiﬁcant CAD
(OR 1.93, 95% CI: 0.65–5.74, P = .24).
3.4. Diagnostic Performance of BNP for Coronary Artery
Disease. In overall patients, SPECT showed a sensitivity of
77.7%, a speciﬁcity of 41.3%, and positive/negative pre-
dictive value of 66.2%/67.1% for detecting coronary artery
disease (Table 4). The most sensitive BNP cut-oﬀ, identiﬁed
by receiver-operating characteristic analysis, was 23.0pg/mL
and sensitivity, speciﬁcity, positive, and negative predictive
value were 70.2%, 56.3%, 65.4%, and 61.7%, respectively.
In patients with positive SPECT (n = 142), plasma BNP
(cut-oﬀ value of 23.0pg/mL) showed a sensitivity of 68.1%,4 Cardiology Research and Practice
Table 1: Baseline characteristics according to the SPECT results.
(+) SPECT (−)S P E C T
TP FP P TN FN P
Patients, n (%) 94 (61.8) 48 (38.2) 55 (67.1) 27 (32.9)
Gender, n (M/F) 59/35 23/25 .09 36/19 18/9 .91
Age, years 64.2 ±9.05 9 .9 ±9.6 .007∗∗ 61.0 ±10.26 4 .9 ±8.0. 1 4
BMI, kg/m2 24.8 ±2.62 6 .2 ±3.8 .07 24.8 ±2.62 5 .2 ±3.1. 6 6
Severity of coronary artery disease
Insigniﬁcant, n (%) 0 (0) 48 (100) 55 (100) 0 (0)
1V D ,n (%) 38 (40.4) 0 (0) 0 (0) 13 (48.1)
MVD, n (%) 56 (59.6) 0 (0) 0 (0) 14 (51.9)
Medical history
DM, n (%) 42 (44.7) 15 (31.2) 0.12 8 (14.5) 10 (37.0) .02∗
HTN, n (%) 73 (77.7) 29 (60.4) 0.03∗ 27 (49.0) 20 (74.1) .03∗
Dyslipidemia, n (%) 44 (46.8) 23 (47.9) 0.90 22 (40.0) 12 (44.4) .70
Smoker, n (%) 38 (40.4) 14 (29.1) 0.16 23 (41.8) 9 (33.3) .72
Laboratory results
Total-C, mg/dL 176.3 ±37.2 177.1 ±35.0 .77 177.2 ±34.8 177.7 ±41.9. 9 6
LDL-C, mg/dL 107.4 ±32.9 107.9 ±28.5 .64 105.3 ±31.9 107.9 ±36.3. 8 8
HDL-C, mg/dL 42.3 ±10.24 6 .0 ±10.1 .43 46.1 ±12.14 3 .6 ±10.6. 0 1 ∗
hs-CRP, mg/dL 0.50 ±1.03 0.35 ±0.57 .39 0.20 ±0.32 0.38 ±0.44 .73
CCr, mL/min 66.7 ±16.87 6 .3 ±21.0 .47 71.3 ±16.56 7 .2 ±15.1. 0 1
BNP, pg/mL¶ 38.5 19.0 .01∗ 22.0 39.0 .002∗∗
(19.0–79.8) (9.3–35.8) (15.0–43.0) (23.0–77.0)
Echocardiographic data
LV EF, % 63 ±56 2 ± 6 .49 62 ±66 4 ±6. 5 4
LA, mm 39.1 ±4.73 8 .4 ±4.9 .80 39.3 ±4.43 9 .0 ±4.2. 9 0
E,m / s 0 .60 ±0.15 0.60 ±0.15 .31 0.59 ±0.16 0.64 ±0.17 .28
A,m / s 0 .76 ±0.18 0.70 ±0.18 .36 0.70 ±0.22 0.76 ±0.27 .30
E/A ratio 0.83 ±0.27 0.89 ±0.33 .35 0.90 ±0.31 0.92 ±0.31 .43
DT, ms 224.4 ±61.9 214.1 ±44.0 .85 232.0 ±61.2 241.8 ±44.7. 7 8
SPECT data
LV EF, % 65.2 ±7.16 6 .0 ±7.9 .69 67.8 ±7.96 6 .1 ±6.7. 7 1
LVEDV, mL 85.7 ±25.48 2 .1 ±20.4 .46 83.8 ±23.08 2 .9 ±24.0. 1 2
LVESV, mL 30.9 ±13.82 8 .7 ±11.5 .48 28.0 ±12.42 8 .8 ±12.0. 4 9
SRS 1.032 ±2.72 0.44±0.92 .46 0.22 ±0.65 0.18 ±0.73 .47
SSS 8.47 ±5.61 2.53 ±2.53 <.001∗∗∗ 2.37 ±3.01 2.15 ±2.31 .45
SDS 7.42 ±4.64 3.27 ±2.52 <.001∗∗∗ 2.15 ±2.78 1.97 ±2.08 .47
∗P<. 05; ∗∗P<. 01; ∗∗∗P<. 001
TP: true positive; FP: false positive; TN: true negative; FN: false negative; BMI: Body mass index, calculated as weight (kg) divided by square height (m2);
VD: vessel disease; MVD: multi-vessel disease; Total C: total cholesterol; LDL-C: Low-density lipoprotein Cholesterol; HDL-C: High density lipoprotein
Cholesterol; CCr: Creatinine clearance rate in milliliters per minute was calculated from the Cockcroft and Gault equation: ((140-age) × weight (kg)/serum
creatinine (mmol/L)), multiplied by a constant of 1.25 in men and 1.03 in women; LV EF: Left ventricular Ejection fraction; LA: Left atrium; E:m i t r a l
peak early diastolic velocity; A: mitral peak late diastolic velocity; DT: E -wave deceleration time; LVEDV: left ventricular end-diastolic volume; LVESV: left
ventricular end-systolic volume; SSS: summed stress score; SRS: summed rest score; SDS: summed diﬀerence score.
†Current or ex-smoker.
¶expressed as median (interpercentile).
a speciﬁcity of 57.1%, and positive/negative predictive value
of 78.0%/50.0%. The area under the receiver-operating
characteristic curve for signiﬁcant coronary artery disease in
overall patients and patients with positive SPECT was 0.673
(95% CI: 0.603–0.743, P<. 001) and 0.694 (95% CI: 0.602–
0.786, P<. 001), respectively (Figure 2).
In terms of territory of ischemia on SPECT, elevated
BNP level (≥23.0pg/mL) predicted signiﬁcant coronary
artery disease on LAD with a sensitivity of 73.7%, a
speciﬁcity of 57.1%, and positive/negative predictive value
of 75.7%/54.5% in patients with perfusion defect on LAD
territory. In patients with perfusion defect on RCA orCardiology Research and Practice 5
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Figure 1: Box plots showing BNP levels (in logarithm) in patients
according to the summed stress score (a) and (b) and angiographic
severity (c). According to summed stress score, patients were
g r o u p e da sm i l d( b e t w e e n4a n d8 ) ,m o d e r a t e( 9 – 1 3 ) ,a n ds e v e r e
(>13). Boxes show median and interquartile ranges and bars
represent upper and lower range limits.
Table 2: Correlation of logarithmically transformed BNP with
clinical variables and parameters of echocardiography and SPECT.
(a) Overall patients (n = 224).
r P
Clinical
Age 0.367 <.001∗∗∗
Creatinine clearance −0.226 .001∗∗
BMI −0.010 .883
Echocardiography
E wave 0.005 .95
A wave 0.194 .008∗∗
Deceleration time 0.019 .801
LA size 0.089 .226
LVEF 0.019 .80
E/A ratio −0.182 .014∗
SPECT
LVEF −0.028 .681
LVESV 0.074 .271
LVEDV 0.064 .35
Summed rest score 0.249 <.001∗∗∗
Summed stress score 0.179 .008∗∗
Summed diﬀerence score 0.106 .12
(b) Patients with true positive SPECT (n = 142).
r P
Clinical
Age 0.393 <.001∗∗∗
Creatinine clearance −0.274 .001∗∗
BMI −0.018 .831
Echocardiography
E wave 0.045 .65
A wave 0.339 <.001∗∗∗
Deceleration time 0.032 .741
LA size 0.108 .249
LVEF 0.043 .649
E/A ratio −0.183 .052
SPECT
LVEF −0.042 .619
LVESV 0.076 .372
LVEDV 0.099 .244
Summed rest score 0.309 <.001∗∗∗
Summed stress score 0.233 .006∗∗
Summed diﬀerence score 0.172 .043∗
∗P<. 05; ∗∗P<. 01; ∗∗∗P<. 001.
BMI: Body mass index E: mitral peak early diastolic velocity; A:m i t r a l
peak late diastolic velocity; LVEF: left ventricular ejection fraction; LVEDV:
left ventricular end-diastolic volume; LVESV: left ventricular end-systolic
volume.
LCx territory, elevated BNP level (≥21.0pg/mL) predicted
signiﬁcantcoronaryarterydiseaseonRCAorLCxwithasen-
sitivity of 71.9%, a speciﬁcity of 65.4%, and positive/negative
predictive value of 82.6%/51.5%.6 Cardiology Research and Practice
Table 3:Multivariateanalysisonpredictorsforsigniﬁcantcoronary
artery disease.
(a) Overall patients (n = 224).
OR 95% CI P
Age 1.005 0.965–1.046 .82
Diabetes mellitus 2.49 1.328–4.683 .004∗∗
Hypertension 2.41 1.29–4.478 .025∗
Creatinine clearance 0.99 0.97–1.006 .48
BNP ≥ 23.0pg/mL 2.75 1.50–5.023 .001∗∗
(b) Patients with positive SPECT (n = 142).
OR 95% CI P
Age 1.00 0.94–1.05 .878
Diabetes mellitus 1.88 0.844–4.174 .122
Hypertension 2.03 0.88–4.63 .09
Creatinine clearance 0.98 0.95–1.00 .081
BNP≥23.0pg/mL 3.34 1.51–7.37 .003∗∗
∗P<. 05; ∗∗P<. 01; ∗∗∗P<. 001.
4. Discussion
In the present study, we found that BNP was the strongest
and independent predictor of CAD in overall patients with
normalleftventricularsystolicfunctionevenaftertheadjust-
ment of age and renal dysfunction. Our results coincide with
the previous study by Kragelund et al. showing that patients
with high NT proBNP level had a signiﬁcantly higher
prevalence of CAD regardless of the left ventricular systolic
function [8]. However, our results show that the role of BNP
in patients with normal left ventricular systolic function as
a diagnostic tool for CAD seems to be limited. BNP (with
cut-oﬀ value 23pg/mL) showed only modest sensitivity and
speciﬁcity for predicting CAD in overall patients and in
patients with negative SPECT (Table 4). This modest predic-
tion level of CAD in patients with normal left ventricular
systolic function and no RWMA (evidence of infarction on
echocardiography) may be explained as follows. First, in our
study, only patients with severe abnormal scan (SSS > 13)
showed signiﬁcantly higher BNP level. This suggests that
mild to moderate degree of inducible myocardial ischemia
may not increase baseline BNP level at rest signiﬁcantly
in patients with normal left ventricular systolic function.
Second, this might be attributed to less correlation between
BNP at rest and inducible myocardial ischemia in patients
without ﬁxed defect on SPECT. There was no signiﬁcant
correlation between BNP and SDS (inducible myocardial
ischemia) in overall patients but only a weak correlation in
patients with positive SPECT. In this study, SRS (perfusion
defect at rest) showed modest but a signiﬁcant correlation
with BNP level in overall patients and patients with positive
SPECT. These ﬁndings suggest that baseline BNP level at rest
is associated with a degree of ﬁxed perfusion defect rather
than inducible ischemia.
In several previous studies, there were controversies
on relationships between BNP and inducible myocardial
ischemia on SPECT. In a previous study by Wong et al.,
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Figure 2: ROC curve of BNP (in logarithm) for predicting CAD
in overall patients (a) and patients (b) with positive SPECT. Area
under ROC curve is 0.673 and 0.694, respectively.
BNP level showed a signiﬁcant correlation with the degree
of reversible ischemia rather than rest score on SPECT
in patients who have neither any history of myocardial
infarction nor evidence of LV systolic dysfunction on SPECT
[21].Thisiscontrarytoourdata.Inourstudy,weperformed
transthoracic echocardiography in all patients and excluded
patients if they showed any RWMA on TTE or pathologic
Q waves on resting electrocardiogram, and all the patients
underwent coronary angiography. After all, we found that
there was only a weak correlation between SDS and BNP
even in patients with true positive SPECT. Another studyCardiology Research and Practice 7
Table 4: Diagnostic performance of BNP and SPECT for coronary artery disease.
Sensitivity, % Speciﬁcity, % PPV, % NPV, %
Predicting CAD in overall patients (n = 224)
SPECT (+) 77.7 41.3 66.2 67.1
BNP ≥ 23.0pg/mL 70.2 56.3 65.4 61.7
Predicting CAD in patients with positive SPECT (n = 142)
BNP ≥ 23.0pg/mL 68.1 62.5 78.0 50.0
Predicting CAD in patients with negative SPECT (n = 82)
BNP ≥ 23.0pg/mL 70.4 54.5 43.2 78.9
BNP ≥ 23.0pg/mL 51.9 74.5 50.0 75.9
Predicting CAD in patients with ischemia on LAD territory (n = 59)
BNP ≥ 23.0pg/mL 73.7 57.1 75.7 54.5
BNP ≥ 23.0pg/mL 64.9 59.0 72.7 50.0
Predicting CAD in patients with ischemia on RCA or LCx territory (n = 83)
BNP ≥ 23.0pg/mL 71.9 65.4 82.0 51.5
BNP ≥ 23.0pg/mL 66.6 69.2 82.6 48.6
PPV: positive predictive value; NPV: negative predictive value.
by Bibbins-Domingo et al. showed that the relation between
elevated BNP level and inducible myocardial ischemia in
patients with stable CAD was evident in patients who had
a history of myocardial infarction, less than those without
history of myocardial infarction [9]. This result accords with
our data and suggests that baseline BNP level may have a
signiﬁcant correlation with ﬁxed defect rather than inducible
myocardial ischemia on SPECT.
In the previous study, SSS > 13 suggested high risk for
cardiac events such as cardiac death and nonfatal myocardial
infarction and candidates for cardiac catheterization and
revascularization [17]. Therefore, if an angina who has
normal left ventricular systolic function and no regional
wall motion abnormality (RWMA) on TTE shows elevated
resting BNP level (even in normal range) which cannot
be explained by any other cause, it may have extensive
CAD and may require invasive management. In our study,
patients with true positive SPECT were older and had
signiﬁcantly lower creatinine clearance than those with false
positive SPECT, but BNP was a signiﬁcant and independent
predictor of CAD after adjustment with these factors (age
and renal dysfunction). In patients with negative SPECT,
however, BNP was not an independent predictor of CAD.
This may be attributed to several reasons. First, we deﬁned
“signiﬁcant CAD” as presence of angiographically critical
coronarylesionsdeﬁnedasgreaterthan70%diametersteno-
sis. Therefore, patients showing negative SPECT who have
intermediate lesion (50%–70% diameter stenosis) might
have elevated BNP level as much as patients with more
than 70% stenosis. Second, multivessel disease was more
frequentamongpatientswithtruepositiveSPECTcompared
to those with false negative SPECT (59.6% versus 51.9%,
resp.) (Table 1). On the other hand, one-vessel disease was
more frequent in patients with false negative SPECT than
those with true positive SPECT (48.1% versus 40.4%, resp.)
(Table 1). The less severe extent of CAD in patients with
false negative SPECT may contribute to the insigniﬁcant
BNPdistributioninnegativeSPECTgroup.Finally,relatively
small number of patients (n = 27) with false negative SPECT
in our study may limit statistical signiﬁcance.
This study had several limitations. First, it analyzed the
retrospective cohort data from a relatively small number of
patients in a single, tertiary referral hospital. Second, we
studied a group of consecutive patients who were referred
to coronary angiography for clinically suspected ischemic
heart disease. Because coronary angiography is often advised
in populations with a higher prevalence of risk factors and
may not be performed in patients with atypical chest pain
and false positive SPECT, the pretest likelihood of CAD was
high in this study. So, the high pretest probability in our
patients would have contributed to the modest sensitivity
of BNP level and SPECT by this selection bias. Third, we
deﬁned signiﬁcant CAD as diameter stenosis >70% and
therefore the diagnostic performance needs be reassessed for
the intermediate lesions. Finally, as BNP is not speciﬁc for
myocardial ischemia and known to be associated to age and
sex, with higher values in females and older individuals, age
and sex-speciﬁc cutoﬀ levels should be redeﬁned.
In conclusion, the diagnostic value of BNP for CAD
in patients with normal left ventricular systolic function is
limited.However,elevatedBNPlevel,asigniﬁcantandstrong
predictor of CAD, may suggest extensive CAD in angina
patients with positive SPECT.
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